Group 1 - Company ST Xiangxue received an administrative penalty from the China Securities Regulatory Commission (CSRC) for false reporting in its 2019 annual report and failure to disclose non-operating fund occupation, resulting in a fine of 6 million yuan [1] - The actual controller Wang Yonghui was warned and fined 10 million yuan, but the company is not subject to major illegal delisting circumstances [1] - The company has restated its financial reports and cleared the non-operating fund occupation by Kunlun Investment, completing the necessary rectifications [1] Group 2 - The company is making positive progress in its judicial reorganization, with the Guangzhou Intermediate People's Court extending the pre-reorganization period to October 11, 2025 [2] - Ongoing work includes debt claim declaration and review, auditing, evaluation, and financial consulting, with selected intermediary institutions for assistance [2] - Successful reorganization is expected to improve the company's asset-liability structure and support sustainable development [2]

Core Viewpoint - ST Xiangxue (300147) has received an administrative penalty decision from the China Securities Regulatory Commission (CSRC) due to information disclosure violations, with some penalties being reduced compared to the prior notice [1] Regulatory Actions - The administrative penalty decision no longer imposes a 5-year market ban on the actual controller Wang Yonghui and removes the warning and 500,000 yuan fine against the former independent director Hao Shiming, while other penalties remain consistent with the prior notice [1] Corporate Restructuring - The Guangzhou Intermediate People's Court has agreed to extend the company's pre-restructuring period until October 11, 2025, during which the company will actively cooperate with the temporary administrator and the court [1] - The company has publicly appointed auditing, evaluation, and financial advisory intermediaries, with the auditing and evaluation work progressing smoothly [1] Business Operations - The company emphasizes the clinical value and market potential of TAEST16001 and is fully advancing the preparatory work for confirmatory clinical trials, with updates to be disclosed according to clinical developments and information disclosure rules [1]

证券代码:300147 证券简称: 香雪制药 公告编号:2025-038 广州市香雪制药股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 雪制药"）及公司实际控制人王永辉收到中国证券监督管理委员会（以下简称"中 国证监会"）下发的《立案告知书》（编号：证监会立案字 0062024028 号、编 号：证监会立案字 0062024029 号），因涉嫌信息披露违法违规，根据《中华人 民共和国证券法》、《中华人民共和国行政处罚法》等法律法规，中国证监会决 定对公司及王永辉立案。2025 年 3 月 21 日，公司收到中国证监会发出的《行政 处罚事先告知书》（广东证监处罚字〔2025〕5 号）。以上具体内容详见公司分 别于 2024 年 9 月 30 日、2025 年 3 月 21 日在巨潮资讯网披露的《关于公司及实 际控制人收到中国证券监督管理委员会立案告知书的公告》 （公告编号:2024-051） 和《关于公司及相关当事人收到 <行政处罚事先告知书> 的公告》 （公告编号:2025- 近日，公司及相关当事人收到中国证券监督管理委员会广东监管局发出的 《行 ...

证券代码:300147 证券简称: 香雪制药 公告编号:2025-038 广州市香雪制药股份有限公司 关于公司及相关当事人收到《行政处罚决定书》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 2024 年 9 月 30 日，广州市香雪制药股份有限公司（以下简称"公司"、"香 雪制药"）及公司实际控制人王永辉收到中国证券监督管理委员会（以下简称"中 国证监会"）下发的《立案告知书》（编号：证监会立案字 0062024028 号、编 号：证监会立案字 0062024029 号），因涉嫌信息披露违法违规，根据《中华人 民共和国证券法》、《中华人民共和国行政处罚法》等法律法规，中国证监会决 定对公司及王永辉立案。2025 年 3 月 21 日，公司收到中国证监会发出的《行政 处罚事先告知书》（广东证监处罚字〔2025〕5 号）。以上具体内容详见公司分 别于 2024 年 9 月 30 日、2025 年 3 月 21 日在巨潮资讯网披露的《关于公司及实 际控制人收到中国证券监督管理委员会立案告知书的公告》（公告编号:2024-051） 和《关于公司及相关当事人收 ...

ST香雪（300147.SZ）8月14日在投资者互动平台表示，截至回复日，公司尚未收到中国证监会广东监 管局出具的《行政处罚决定书》。 每经AI快讯，有投资者在投资者互动平台提问：请问目前处罚申述进展如何？ （文章来源：每日经济新闻） ...

人民财讯8月13日电，企查查APP显示，近日，北京杜德生物科技有限公司成立，注册资本1000万元， 经营范围包含：第二类医疗器械销售；人体基因诊断与治疗技术开发；工程和技术研究和试验发展；生 物化工产品技术研发等。企查查股权穿透显示，该公司由广州杜德生物科技有限公司等共同持股，后者 大股东为ST香雪（300147）。 ...

Group 1 - The stock price of ST Xiangxue (300147) closed at 7.68 yuan on August 11, 2025, down 1.29% with a turnover rate of 2.05% and a trading volume of 134,500 hands, amounting to 103 million yuan [1] - The latest financial report for ST Xiangxue shows total operating revenue of 421 million yuan for Q1 2025, a year-on-year decrease of 25.99%, and a net profit attributable to shareholders of 87.73 million yuan, down 146.03% year-on-year [1] - The company has a current ratio of 0.277, a quick ratio of 0.223, and a debt-to-asset ratio of 81.75% [1] Group 2 - ST Xiangxue has made investments in 40 enterprises and participated in 2,157 bidding projects [2] - The company holds 244 trademark registrations and 165 patent registrations, along with 251 administrative licenses [2]

Core Viewpoint - The company emphasizes the clinical value and market potential of its new drug TAEST16001 and is actively advancing the preparatory phase of confirmatory clinical trials [2]. Group 1 - The company is committed to keeping investors informed about the clinical progress of TAEST16001 and the status of its pre-restructuring efforts [2]. - The company plans to disclose updates regarding the new drug development and pre-restructuring progress in accordance with information disclosure regulations [2]. - Investors are encouraged to pay attention to the company's announcements for further details [2].

公司回答表示：您好，感谢对公司的关注。TAEST16001的临床试验方案中有明确目标患者的肿瘤抗原 表达检测标准。在相关研究中并未采用类器官模型等技术进行患者筛选或药效验证。谢谢！责任编辑： 栎树 金融界7月31日消息，有投资者在互动平台向ST香雪提问：根据公开资料，TAEST16001是TCR-T细胞 疗法，需针对肿瘤抗原设计。请问在II期临床试验中，是否已明确目标患者的肿瘤抗原表达检测标准？ 针对软组织肉瘤的异质性，是否采用类器官模型等技术进行患者筛选或药效验证？ ...

Group 1 - The Anhui Provincial Drug Supervision Administration announced that a product from Bozhou Huqiao Pharmaceutical Co., Ltd. (a subsidiary of Guangzhou Xiangxue Pharmaceutical Co., Ltd.) failed to meet quality standards, specifically regarding its characteristics [1][2] - The announcement revealed that a total of 15 varieties and 16 batches of drugs were found non-compliant with standards, including issues related to characteristics, total ash, dissolution rate, moisture, weight variation, and identification [1] - The specific product in question, Winter Melon Seed, was sampled from Susong County Traditional Chinese Medicine Hospital, with the batch number 1901070142, and was tested against the Anhui Province Chinese Medicine Decoction Pieces Processing Specification 2015 edition [1][3] Group 2 - Huqiao Pharmaceutical was established on December 21, 2010, and is primarily engaged in the production and sale of traditional Chinese medicine pieces, including toxic pieces, as well as other food products [2] - Xiangxue Pharmaceutical holds a 70% stake in Huqiao Pharmaceutical and has been recognized as a leading enterprise in the modernization of traditional Chinese medicine, focusing on various health-related sectors [2]